Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark Lappe
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 110
- Beta
- 3.82
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.63
Financials
Revenue
$0.00-100.0%Net Income
$-36.65MEBITDA
$-30.48MFree Cash Flow
$-29.89MEPS (diluted)
$-2.34Shares Outstanding (diluted)
15.67M-13.7%Operating Expenses
$32.15MCash & Debt
$133.34MReturn of Capital
$0.00Revenue by Segment (annual)
$1.30MDividend per Share
$0.85Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.30M | $-140.06M | $-9.04 |
| 2024 | $200.0K | $1.69B | $116.58 |
| 2023 | $1.80M | $-241.36M | $-5.12 |
| 2022 | $2.19M | $-145.23M | $-3.62 |
| 2021 | $7.13M | $-81.77M | $-2.15 |
| 2020 | $12.81M | $-76.12M | $0.00 |
| 2019 | $9.09M | $-51.40M | $-1.41 |
| 2018 | $8.60M | $-31.16M | $-1.15 |
| 2017 | $8.39M | $-19.44M | $-0.68 |
| 2016 | $6.67M | $-8.27M | $-0.23 |
Valuation
INBXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (6)
- Newsprnewswire.com·12d ago·Positive
Inhibrx Announces Participation in Upcoming Scientific Conferences SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 2026 European Society for Medical Oncology (ESMO) Congress October 25 th , 2026 – Madrid, Spain Title: HexAgo…
View source ↗ - Newsmarketbeat.com·23d ago·Positive
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup Inhibrx Biosciences TodayINBXInhibrx Biosciences$97.93 -2.15 (-2.15%) As of 10/1/2026 04:00 PM Eastern52-Week Range$28.16▼$155.29Price Target$197.50Add to WatchlistAfter a decisive clinical outperformance that the broader market inexplicably sold off, Inhibrx Biosciences NASDAQ: INBX CEO deployed more than $3.6 million of personal capital to buy shares. With about 28% of the public float sold short and a major FDA approval…
View source ↗ - Newsfool.com·39d ago·Positive
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? The purchase of 25,000 shares for ~$2.6 million was executed at a weighted average price of $105.82 per share on September 8, 2026. The transaction size was equal to 3% of the total equity stake held before the filing.
View source ↗ - Newsseekingalpha.com·41d ago·Positive
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106 Inhibrx Biosciences (INBX) maintains a "Strong Buy" rating, driven by major clinical and regulatory milestones for ozekibart and INBRX-106. Ozekibart's BLA for unresectable/metastatic chondrosarcoma was accepted by the FDA, with a PDUFA target action date of April 14, 2027. Company reported positive interim data for ozekibart in 3rd/4th-line CRC and strong phase 2 results for INBRX-106 plus KE…
View source ↗ - Newsseekingalpha.com·46d ago·Neutral
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets, with an FDA BLA decision for ozekibart due by April 2027. Ozekibart delivered a 52% risk reduction in chondrosarcoma progression and strong response rates in colorectal and Ewing sarcoma cohorts, fueling prior share price surges. INBRX-106, combined with Keytruda, showed a 48.3% cORR in head and neck cancer in data…
View source ↗ - Newsprnewswire.com·51d ago·Neutral
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study – Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.
View source ↗
Earnings
Fri, Nov 13(in 3 weeks)
Consensus estimate $-2.45 per share
Typical surprise -2.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-2.34 vs $-2.28miss
- Thu, May 14$-2.15 vs $-2.37beat
- Thu, Mar 19$-2.11 vs $-2.08miss
- Fri, Nov 14$-2.28 vs $-2.08miss
- Wed, Aug 13$-1.85 vs $-2.92beat
- Wed, May 14$-2.80 vs $-2.55miss
Estimates and results for INBX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INBX officers and directors.
- Bought
- $16.2m
- Sold
- $21.9m
42 trades
9 trades
- Lappe Markbought
- Lappe Markbought
- Lappe Markbought
- Lappe Markbought
- Lappe Markbought
- Lappe Markbought
- Lappe Markbought
- Lappe Markbought
49 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INBX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.